Eli Lilly Gains as Novo Nordisk Trial SetbackNovo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands.The trial showed a weight loss of 20.2% with CagriSema versus 23.6% with tirzepatide, leading to a significant drop in Novo Nordisk shares.The REDEFINE 4 trial involved 809 subjects over 84 weeks, and while CagriSema demonstrated a safe profile, the results did n ...

Group 1 - Investors have taken a bullish stance on Eli Lilly, with significant options trades indicating potential upcoming movements [1][2] - The overall sentiment among large traders is 61% bullish and 23% bearish, with a total of 26 uncommon options trades identified [2] - The targeted price range for Eli Lilly over the last three months is between $920.0 and $1220.0 [3] Group 2 - The mean open interest for Eli Lilly options trades is 381.0, with a total volume of 3,731.00 [4] - Eli Lilly is a pharmaceutical company focusing on neuroscience, cardiometabolic, cancer, and immunology, with key products including Verzenio, Mounjaro, and Taltz [5] - Recent analyst ratings suggest an average target price of $1289.6 for Eli Lilly [7] Group 3 - Eli Lilly's current trading volume is 613,828, with a price increase of 3.16%, now at $1041.46 [8]

Core Insights - Eli Lilly's Zepbound (tirzepatide) has received FDA approval for a label expansion to include a four-dose single-patient use KwikPen, enhancing patient access and convenience [1][2] - Zepbound is the most prescribed injectable obesity management medication, with patients losing an average of up to 50 pounds, demonstrating strong efficacy [1][2] - The introduction of the KwikPen aims to support patients in their weight management journey, with a self-pay price starting at $299 per month [1][2] Product Details - Zepbound is available in multiple doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, with the 2.5 mg serving as a starting dose [1][2] - The recommended maintenance doses for weight reduction are 5 mg, 10 mg, or 15 mg, administered subcutaneously once per week [1][2] - Zepbound is indicated for adults with obesity or overweight with weight-related medical problems, and it is also FDA-approved for treating moderate-to-severe obstructive sleep apnea [1][2] Clinical Efficacy - In the SURMOUNT-1 trial, participants taking Zepbound 15 mg lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% with placebo [1][2] - In the SURMOUNT-5 trial, participants on Zepbound experienced an average weight loss of 50 lbs (20.2%), while those on Wegovy lost an average of 33 lbs (13.7%) [1][2] Market Impact - In 2025, over 1 million patients accessed Lilly treatments through LillyDirect, which offers self-pay pricing at a 50% or greater discount compared to other GLP-1 medications [1][2] - One out of every three new patients starting a branded weight management medication was prescribed Zepbound self-pay vials in 2025, indicating strong market demand [1][2] Digital Health Platform - LillyDirect is a digital health platform that connects patients with chronic conditions to necessary care and prescribed medicines, facilitating prescription fulfillment through licensed healthcare providers [2][3]

Core Insights - Eli Lilly has launched a new multi-dose injection pen for its obesity drug Zepbound, named KwikPen, which offers a month's worth of doses in a single device [1][3] - The price for the KwikPen starts at $299 per month for the lowest dose level, available through Lilly's direct-to-consumer platform, LillyDirect [1][3] - The introduction of the KwikPen aims to enhance patient convenience by reducing the number of devices needed for treatment, as it allows patients to take four weekly doses with one pen [2][3] Market Performance - Zepbound has seen significant demand since its market entry in late 2023, contributing to Eli Lilly's majority share in the weight-loss drug market, overtaking rival Novo Nordisk [3][4] - In the fourth quarter, Zepbound generated $4.2 billion in U.S. revenue, marking a 122% increase compared to the previous year [4] - The FDA has approved a label expansion for Zepbound to include the new multi-dose device, indicating regulatory support for the product's growth [4] Strategic Commitment - Eli Lilly emphasizes its commitment to supporting individuals with obesity through innovative treatment options like the Zepbound KwikPen, which is already trusted for other Lilly medications [5]

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Ryan Maynard will join the company as Chief Financial Officer (CFO) on February 23, 2026. Mr. Maynard joins Foghorn with over 25 years of executive experience driving financial strategy, capital markets execution, and operational performance across publ ...

Novo shares slump after the Danish drugmaker's experimental obesity drug fails to beat Lilly's treatment in an 84-week trial. ...

Core Viewpoint - Nvidia shares have increased as investors anticipate the company's fourth-quarter earnings report, which is expected to provide insights into the demand for artificial intelligence [1] Company Summary - Nvidia is preparing to release its fourth-quarter earnings, which will likely indicate the current state of demand for artificial intelligence products [1]

Core Viewpoint - Novo Nordisk shares faced pressure due to a head-to-head study indicating that its drug in development was less effective in weight loss compared to a product from Eli Lilly [1] Company Summary - Novo Nordisk is a Danish pharmaceutical company currently experiencing challenges with its drug development [1] - The company's recent study results have raised concerns about its competitive position in the market against Eli Lilly [1] Industry Summary - The pharmaceutical industry is witnessing intense competition, particularly in the weight loss drug segment, where efficacy is a critical factor for market success [1] - Eli Lilly's product has set a benchmark that other companies, including Novo Nordisk, must meet or exceed to remain competitive [1]

Core Viewpoint - Novo Nordisk's stock experienced a decline of over 10% following the announcement that its next-generation weight loss drug, CagriSema, did not meet its primary target of non-inferiority in weight loss compared to Eli Lilly's drug, tirzepatide, after 84 weeks [1] Group 1 - CagriSema failed to achieve its primary endpoint in the clinical trial [1] - Eli Lilly's stock saw an increase of 2.1% in premarket trading as a result of Novo Nordisk's announcement [1] - Novo Nordisk is considering additional trials for CagriSema, including testing higher-dose combinations [1]

Group 1 - Novo Nordisk's experimental obesity drug CagriSema did not meet the primary endpoint in a trial aimed at demonstrating non-inferiority to Eli Lilly's Tirzepatide in terms of body weight reduction [1] - The trial results indicate a setback for Novo Nordisk in the competitive obesity drug market, where Eli Lilly's Tirzepatide has shown strong performance [1] - This development may impact Novo Nordisk's market position and future growth prospects in the obesity treatment sector [1]